Date: 2011-06-01
Type of information: Private placement
Company: Swedish Orphan Biovitrum - SOBI (Sweden)
Investors:
Amount: SEK 637 million (€71 million)
Funding type: rights issue
Planned used:
Others: Swedish Orphan Biovitrum has announced that its rights issue with preferential rights for the Company\'s shareholders has been fully subscribed and the underwriting commitments do not need to be utilized. The subscription period of the rights issue ended on May 26, 2011. Approximately 99.9% of the offered shares have been subscribed for with subscription rights and an additional 0.1% have been subscribed for without subscription rights. In total, applications for non-preferential subscription have been received corresponding to approximately 81% of the total number of new shares. The subscription price was SEK 12 per new share and the Company\'s shareholders were entitled to subscribe for one new share for each four existing shares held.
The rights issue provides Swedish Orphan Biovitrum with proceeds of approximately SEK 637 million (€71.8 million) before transaction costs. Pursuant to the rights issue, Swedish Orphan Biovitrum\'s share capital will increase by SEK 29,105,800 to approximately SEK 146,664,000. The number of shares will increase by 53,045,319 common shares to a total of 267,295,132 shares. The rights issue is expected to be registered with the Swedish Companies Registration Office around June 8, 2011 and trading in the new shares on NASDAQ OMX Stockholm is expected to start on June 10, 2011.
Therapeutic area: Rare diseases - Genetic diseases
